Emerson Electric Co. vs IDEXX Laboratories, Inc. — how do they compare? Emerson Electric Co. trades at $163.8 (market cap $91.69B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Emerson Electric Co. is the larger of the two by market cap, and Emerson Electric Co. pays a 1.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| EMR | IDXX | |
|---|---|---|
Market Cap | $91.69B | $46.22B |
Sector | Industrials | Health |
52-Week High | $164.38 | $766.68 |
52-Week Low | $123.30 | $526.44 |
Enterprise Value | $102.77B | $47.12B |
Dividend Yield | 1.35% | — |
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $164.02, up 3.36% with strong technical momentum and bullish analyst sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding expectations. Recent acquisition of Glue Inc. enhances AI capabilities in test & measurement, supporting the raised 2026 outlook. Valuation metrics show P/E of 35.97 and P/S of 4.97, while profitability remains solid with 13.83% net margin.
EMR presents a favorable risk-reward profile with consensus price target of $171.33 offering 4.5% upside potential. Strong organic growth and AI integration drive optimism, though elevated valuation and overbought technical indicators warrant caution. The stock's proximity to 52-week highs suggests near-term consolidation may precede further gains based on execution of growth initiatives.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →